#biomarker
Latest news and interesting information about biomarker.
Savara Presents Molgramostim Biomarker Data at ATS
Savara presented molgramostim biomarker data from IMPALA-2 Phase 3 trial at ATS 2026. Key results show improved lung function and biomarker reductions.
Oppenheimer Reiterates Outperform on UroGen Pharma
Oppenheimer reiterates Outperform on UroGen Pharma with $40 target. Strong commercial momentum for Zusduri driven by physician enthusiasm.
DT-216P2 Shows Promise in Friedreich Ataxia Trial
Design Therapeutics announces positive Phase 1/2 trial data for DT-216P2 in Friedreich ataxia, showing clinical improvements and good tolerability.
Caris Identifies 13,293 Patients Eligible for New Cancer Therapies
Caris Life Sciences identifies 13,293 patients eligible for new cancer therapies via Lookback Program, covering 10 tumor types.
Biogen Stock: Alzheimer Drug Shows Promise
Biogen's Alzheimer drug diranersen shows positive Phase 2 results. Stock analysis and future outlook from Bond.az.
Proteome Sciences reports progress in services, reagent sales
Proteome Sciences plc reports progress in services business and continued recovery in TMT and reagent sales at AGM.
Diet reverses biological age in 4 weeks
University of Sydney study shows 4-week diet reduces biological age in elderly adults.
...